Navigation Links
New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
Date:3/31/2008

logical translational and biomedical research and a distinguished fellow of cardiovascular science at CV Therapeutics.

In November 2007, the Company announced that the U.S. Food and Drug Administration was reviewing potential claims to promote Ranexa for HbA1c reduction in coronary artery disease patients with diabetes.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Regadenoson has not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, includi
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... YORK , June 19, 2013 ... brand new infographic summary of the results from ... a third of all respondents stated that CROs would be ... 50% of respondents will be running 6 or more clinical ... with the Clinical Trial Supply USA ...
(Date:6/18/2013)... YORK , June 18, 2013  Intercept Pharmaceuticals, ... biopharmaceutical company focused on the development and commercialization of ... today announced the pricing of an underwritten public offering ... public offering price of $33.01 per share.  In addition, ... purchase up to an additional 259,500 shares of common ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... PLAINS, N.Y., AUG. 2 Two major studies,published today ... doctors,better identify pregnant women at risk for preterm delivery ... Foundation said today. In one large multi-center trial ... (most of whom had no prior history of preterm ...
... - Access to Large Population of Glioblastoma Patients Expected ... Phase ll Study of Promising New Approach -, ... PPHM ), a clinical stage biopharmaceutical,company developing targeted monoclonal ... infection, today announced that the first,patient has been administered ...
Cached Medicine Technology:Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 2Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 3Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India 4
(Date:6/19/2013)... 2013) In early April, senior leaders from medical, ... Connecticut, to discuss one question: how can first responders ... , The preliminary results of this discussion are now ... The Hartford Consensus ," a concept paper published in ... of Trauma and Acute Care Surgery , official ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Effective Environmental Services ... of new websites. These online links are devoted to a ... Tank cleaner, Organic Odor Control Mold Magician and others. , ... fish and animals in the water as well as living ... sludge buildup that can accumulate at the bottom of a ...
(Date:6/19/2013)... Ky. (PRWEB) June 19, 2013 Dental ... during sedation because from minor to moderate sedation, a ... Oregon Board of Dentistry is the latest to update ... moderate and deep sedation in an effort to increase ... the Oregon Dental Practice Act goes into effect July ...
(Date:6/19/2013)... Brightree LLC , the leading provider of cloud-based ... care industry, has been ranked for the first time - ... (HCI 100) list. This prestigious list features the top ... revenue during the last fiscal year. Since 2005, Brightree’s revenue ... the company has built its organization to more than 500 ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 At a Travel ... positive changes and growth that has occurred over the last ... club. , Shuman said, "Travel Services has added vendors, lowered ... beyond belief. Membership is up, even in the tough ... the demands of members." , Having been in the Travel ...
Breaking Medicine News(10 mins):Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Effective Environmental Services Launch New Websites to Serve Customers 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 2Health News:Required Capnography Monitoring Growing Trend Among National and State Healthcare Organizations 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2
... 8, 2011 - The Sea Grant programs of Connecticut ... grants valued at $1,130,832 to six projects that will look ... health of Long Island Sound, a water body designated by ... , Research results from five two-year projects and a one-year ...
... NC A UNC study released this week in the ... of squamous cell carcinoma of the oral tongue in young ... decades. A team of researchers from UNC Lineberger ... Surveillance, Epidemiology and End Results (SEER) database and found that, ...
... News) -- The percentage of personal bankruptcies caused by ... since Massachusetts began requiring people to buy health insurance ... challenges the Obama administration,s claim that medical bankruptcies will ... is largely patterned after the Massachusetts law, according to ...
... 2011 issue of the journal Heath Affairs ... implemented and tested by researchers and clinicians from Indiana ... Geriatric Resources for Assessment and Care of Elders (GRACE) ... lower income, older adults. GRACE is now in use ...
... physician-scientists at University Hospitals (UH) Case Medical Center are ... an early stage, aggressive type of breast cancer. ... of Breast Cancer Research at UH Case Medical Center,s ... breast cancer. Patients with this form of breast ...
... This release is available in Spanish and ... found to be 2.3-fold higher among Muslim adolescents than among ... the former group. Finally, as a general conclusion, an average ... disorder, and 15% suffers body dissatisfaction. These were the conclusions ...
Cached Medicine News:Health News:Sea grant awards more than $1.1 million for research under EPA's Long Island Sound study 2Health News:Sea grant awards more than $1.1 million for research under EPA's Long Island Sound study 3Health News:UNC study finds oral tongue cancer increasing in young, white females 2Health News:Mass. Health Reform Hasn't Halted Medical Bankruptcies 2Health News:Aging with grace: In-home assessments lead to better care, lower health costs 2Health News:Aging with grace: In-home assessments lead to better care, lower health costs 3Health News:Novel clinical trial aims to reduce recurrence of aggressive breast cancer 2Health News:Eating disorders and body dissatisfaction is double in Muslim teenagers than in Christian 2
... Steerability - Use the Attain Prevail's ... catheters and guide wires, to obtain the ... Inject contrast media for improved visualization of ... needed with tip deflection. Telescoping - ...
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
... Mosaic, the third generation tissue valve from ... tissue valve available. The Mosaic valve builds ... and is an excellent choice for patients ... with a tissue valve. For more than ...
... Mitral bioprosthesis is a portrait ... based on 25 years of ... makes it an excellent choice ... replacement--particularly elderly patients and those ...
Medicine Products: